Featured Post

OOS Investigation Tools: Streamlining Out-of-Specification Investigations

by
OOS Investigation Tools: Streamlining Out-of-Specification Investigations Out-of-specification (OOS) events are critical occurrences in pharmaceutical manufacturing, representing deviations from established specifications and potentially impacting product quality and patient safety. Efficient and thorough investigations are crucial to identify root causes, prevent recurrence, and ensure product compliance. This post explores essential tools that streamline OOS investigations. Key Tools and Examples of OOS investigation Tools: 1. Electronic Data Capture (EDC) Systems:   These systems are crucial for managing clinical trial data, but their principles of data integrity, audit trails, and secure storage are highly relevant to OOS investigations. Veeva Vault EDC: Veeva is a well-established name in the life sciences industry. Vault EDC is a cloud-based platform specifically designed for clinical data management. Its features like audit trails, electronic signatures, and version contro...
0

FDA requirements on oos investigation in pharmaceutical industry

by

The FDA outlines expectations for investigating Out-of-Specification (OOS) test results in the pharmaceutical industry through its guidance document: 

"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision".

#oos-investigation

Here's a breakdown of the key requirements:

Whenever an OOS result is obtained, an investigation must be conducted (§ 211.192). An OOS result refers to any test result falling outside the established specifications or acceptance criteria. This applies to:

  • Tests on active pharmaceutical ingredients (APIs)
  • Excipients and other components
  • In-process materials
  • Finished drug products

The investigation should determine the source of the OOS result:

  • Was it an error in the measurement process (analytical aberration)?
  • Did it originate from an aberration in the manufacturing process?

The investigation should be:

  • Scientifically sound: Based on scientific principles and methodologies.
  • Thorough: Comprehensively evaluate all potential factors.
  • Timely: Investigate promptly to minimize delays and potential impact.
  • Unbiased: Objectively assess all available data.
  • Well-documented: Maintain detailed records of the investigation process and findings.

The FDA recommends a two-phased approach:

  • Phase I: Laboratory Investigation

    • Review the test method with laboratory personnel.
    • Verify the analyst's performance of the test procedure.
    • Examine raw data and identify anomalies.
    • Confirm calculations and absence of unauthorized changes.
    • Ensure proper use of reference standards, solvents, and reagents.
    • Evaluate the test method's performance compared to validation data.

  • Phase II: Full-Scale OOS Investigation (if necessary)

    • This may involve a production process review and/or additional laboratory work.
    • The goal is to identify the root cause of the OOS and take corrective and preventive actions (CAPA).
    • The investigation may need to expand beyond the laboratory if the cause is suspected to originate in the manufacturing process.
    • The impact of the OOS result on already distributed batches needs to be evaluated.

Overall, the focus of the OOS investigation is to:

  • Understand the cause of the OOS result.
  • Prevent similar occurrences in the future.
  • Ensure the quality and safety of the drug product.

Additional Notes:

  • The specific requirements for OOS investigations may vary depending on the complexity of the product and the severity of the OOS result.
  • Pharmaceutical companies should have established procedures for conducting OOS investigations.
  • Consulting the full FDA guidance document is recommended for a more comprehensive understanding of the expectation.
Also Read:


Comments

Post a Comment

If you have any doubt please let me know. Thank you.